Roche upgraded at Morgan Stanley on growth, pipeline upside (RHHBY:OTCMKTS)
· seekingalpha.com
Morgan Stanley upgrades Roche to overweight, boosting PT to $63 on giredestrant and trontinemab catalysts. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...